Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

This study has been terminated.
(low accrual)
Sponsor:
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT00524316
First received: August 31, 2007
Last updated: May 19, 2014
Last verified: May 2014

August 31, 2007
May 19, 2014
April 2007
December 2010   (final data collection date for primary outcome measure)
Progression-free Survival at 4 Months [ Time Frame: 4 months ] [ Designated as safety issue: No ]
Response rate as measured by dynamic contrast-enhanced (DCE) CT scans
Complete list of historical versions of study NCT00524316 on ClinicalTrials.gov Archive Site
  • Overall Survival [ Time Frame: Every 6 months after removal from treatment till death ] [ Designated as safety issue: No ]
    median survival in months
  • Tissue Perfusion, Ktrans, IAUC, and Percent Viable Tumor as Measured by DCE-MRI at Baseline and on Days 8 (Before Transarterial Chemoembolization), 10, and 35 [ Time Frame: Baseline, day 8, day 10, day 28 and day 35 ] [ Designated as safety issue: No ]
  • Safety and Tolerability [ Time Frame: Daily while on treatment ] [ Designated as safety issue: Yes ]

    Number of participants with adverse advent.

    Please refer to adverse event reporting for more detail.

  • Quality of Life as Measured by the FACT-HEP Scale Prior to Each Course of Therapy [ Time Frame: Every 6 weeks ] [ Designated as safety issue: No ]
  • Tumor Marker Response (AFP) [ Time Frame: Baseline, week 7 and every 6 weeks after ] [ Designated as safety issue: No ]
  • Overall survival
  • Progression-free survival
  • Tissue perfusion, Ktrans, IAUC, and percent viable tumor as measured by DCE-MRI at baseline and on days 8 (before transarterial chemoembolization), 10, and 35
  • Safety and tolerability
  • Quality of life as measured by the FACT-HEP scale prior to each course of therapy
  • Tumor marker response (AFP)
Not Provided
Not Provided
 
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A Phase II Study of SUNITINIB MALATE (Sutent) and Chemoembolization in Patients With Unresectable Hepatocellular Cancer

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs, such as doxorubicin, near the tumor. Giving sunitinib together with chemoembolization may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving sunitinib together with chemoembolization works in treating patients with liver cancer that cannot be removed by surgery.

OBJECTIVES:

Primary

  • To determine the progression-free survival at 4 months of patients treated with this regimen.

Secondary

  • To determine overall survival of these patients.
  • To determine if dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can be used to measure decrease in tumor perfusion and vascular permeability as a result of treatment with sunitinib malate in combination with TACE, and if it can be useful in prognosis.
  • To examine the safety and tolerability of this regimen.
  • To determine if a change in circulating endothelial precursor cell number and total monocyte count on days 3, 8, 10, and 35 of therapy (as compared with levels at baseline) and decrease in soluble vascular endothelial growth factor receptor-2 in serum on days 8 (before TACE), 10, and 35 of therapy (as compared with baseline) correlate with improved response and survival.
  • To determine the effect of this therapy on quality of life as measured by the FACT-HEP scale prior to each course of therapy.

OUTLINE: This is a multicenter study.

Patients receive oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses. Patients undergo hepatic artery chemoembolization with doxorubicin hydrochloride on day 8 of course 1 only. Treatment with sunitinib malate repeats every 6 weeks* in the absence of disease progression or unacceptable toxicity.

NOTE: *Course 1 is 7 weeks in duration; all subsequent courses are 6 weeks in duration.

Blood samples are collected at baseline and periodically during study to measure circulating endothelial precursor cell levels, total monocyte count, and soluble vascular endothelial growth factor receptor-2.

Quality of life is assessed by the FACT-HEP scale at baseline, prior to each course of treatment, and then at the completion of treatment.

After completion of study treatment, patients are followed every 6 months.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Liver Cancer
  • Drug: doxorubicin hydrochloride
    Transarterial chemoembolization
  • Drug: sunitinib malate
    Given Orally
  • Other: laboratory biomarker analysis
    Correlative Study
  • Procedure: hepatic artery embolization
    Surgical procedure
  • Procedure: quality-of-life assessment
    Correlative Study
Experimental: Sunitinib
oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
Interventions:
  • Drug: doxorubicin hydrochloride
  • Drug: sunitinib malate
  • Other: laboratory biomarker analysis
  • Procedure: hepatic artery embolization
  • Procedure: quality-of-life assessment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
16
May 2014
December 2010   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically, cytologically, or serologically* confirmed hepatocellular carcinoma meeting the following criteria:

    • 1-4 lesions
    • Involvement of 1 or both liver lobes NOTE: *Alpha-fetoprotein (AFP) > 500 mcg/L in high-risk patients
  • Measurable disease by CT scan or MRI

    • Disease does not exceed 50% of the liver parenchyma
    • At least 1 lesion ≥ 3 cm in longest diameter
  • Tumor burden involves < 50% of the liver
  • Refused surgery OR unresectable disease due to any of the following:

    • Multifocality
    • Advanced cirrhosis
    • Comorbid illness
  • Candidate for chemoembolization
  • No fibrolamellar histology
  • No ascites
  • No known brain metastases

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Life expectancy ≥ 12 weeks
  • WBC ≥ 3,000/mm³
  • ANC ≥ 1,500/mm³
  • Hemoglobin ≥ 8.5 g/dL (transfusion allowed)
  • Platelet count ≥ 100,000/mm³
  • Bilirubin ≤ 2 mg/dL
  • AST ≤ 5 times upper limit of normal (ULN)
  • INR < 1.5
  • Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min
  • No bleeding diathesis or coagulopathy
  • No active congestive heart failure
  • No uncontrolled angina
  • No myocardial infarction within the past 12 months
  • No cardiac arrhythmia
  • Ejection fraction ≥ 45% (in patients with known coronary artery disease and in patients > 50 years of age)
  • Child-Pugh class A or B cirrhosis
  • No impedance of hepatopedal blood flow (portal vein thrombosis)
  • No thrombosis of the main portal vein
  • No encephalopathy
  • No biliary obstruction
  • No variceal bleed within the past 6 months
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate
  • No absolute contraindication to doxorubicin, iodinated contrast material, microfibrillar collage hemostat, or dexamethasone
  • No other concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Psychiatric illness or social situation that would limit compliance with study requirements
  • No other active malignancies within the past year except nonmelanoma skin cancer or carcinoma in situ
  • No significant traumatic injury within the past 4 weeks
  • No QTc prolongation (i.e., QTc interval ≥ 500 msec) or other significant ECG abnormalities
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after the completion of study treatment

PRIOR CONCURRENT THERAPY:

  • Recovered from prior therapy
  • Prior liver-directed therapy, such as chemoembolization, radiofrequency ablation, cryoablation, or ethanol injection allowed if the following criteria are met:

    • Treated lesion remains inactive by CT scan or MRI and new lesion being embolized is distinct from the previously treated lesion
    • Radiographic progression of previously treated lesion requiring re-embolization
  • Prior liver resection allowed
  • Prior immunotherapy allowed
  • No prior antiangiogenesis therapy
  • No prior liver transplantation

    • Patients awaiting a cadaveric or orthotopic liver transplantation are eligible provided they have end-stage liver disease with a priority score of < 20 points
  • More than 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas or mitomycin C)
  • More than 4 weeks since prior major surgery or open biopsy
  • At least 1 week since prior fine needle biopsy
  • No concurrent immunotherapy
  • No concurrent radiotherapy
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)

    • Doses of ≤ 1 mg/day are allowed for prophylaxis of thrombosis as long as INR ≤ 1.5
    • Both full dose and prophylactic dose low molecular weight heparin allowed as long as PT INR ≤ 1.5
  • No anticipated major surgery during and for 3 months after completion of study treatment
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00524316
CDR0000563261, RPCI-I-82706
Yes
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Not Provided
Principal Investigator: Renuka Iyer, MD Roswell Park Cancer Institute
Roswell Park Cancer Institute
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP